Genrix Bio

688443 · SSE STAR Market

Public Market Listing

688443SSE STAR Market

SSE STAR Market primary exchange listing

Live quotes, historical charts, and market capitalization for Genrix Bio are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
IL-4R-alphaMonoclonal antibody
Atopic Dermatitis
Phase 3
BCMA x CD3Multispecific antibody
Multiple Myeloma
Phase 1
TSLPMultispecific antibody
Atopic Dermatitis

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
May 2027 (2)
Velinotamig (GR1803)Phase 2Multiple Myeloma
Est. primary completion 2027-05-12 · NCT06566547 · CT.gov ↗
What to watch
TelikibartPhase 3Allergic Rhinitis, Seasonal
Est. primary completion 2027-05-15 · NCT07199257 · CT.gov ↗
What to watch
June 2027 (1)
Velinotamig (GR1803)Phase 1/2Systemic Lupus Erthematosus, Auto Immune Disease
Est. primary completion 2027-06-01 · NCT07348055 · CT.gov ↗
What to watch
July 2027 (1)
Velinotamig (GR1803)Phase 2Multiple Myleoma
Est. primary completion 2027-07-01 · NCT06952075 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Velinotamig (GR1803)Phase 1/2Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Est. primary completion 2029-01 · NCT07738822 · CT.gov ↗
What to watch
March 2029 (1)
Velinotamig (GR1803)Phase 3Multiple Myeloma
Est. primary completion 2029-03 · NCT07452198 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

3 October 2026Topline resultGR1802Telikibart Phase 3 in atopic dermatitis meets both coprimary endpoints
Genrix Bio · Source ↗
July 2026Filing acceptedTelikibartNMPA accepts the resubmitted marketing application for telikibart (GR1802) in adult moderate-to-severe atopic dermatitis (July 2026); under review
CN, NMPA · Chongqing Genrix Biopharmaceutical · Source ↗
February 2026Filing acceptedTelikibartNMPA accepts the marketing application for telikibart (GR1802) in adult seasonal allergic rhinitis (February 2026)
CN, NMPA · Chongqing Genrix Biopharmaceutical · Source ↗
January 2026Filing acceptedVelinotamig (GR1803)China's NMPA accepts the conditional marketing application for velinotamig, with priority review
CN, NMPA · Genrix Bio · Source ↗

Financial reports

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$32M$66M—$19Mreport ↗